XWEL vs MNST vs HIMS vs CELH vs SKIN

For growth investors, Celsius Holdings, Inc.

(CELH) is the stronger pick with 85. 5% revenue growth year-over-year, versus -13. 8% for XWELL, Inc. (XWEL). Monster Beverage Corporation (MNST) offers the better valuation at 39. 2x trailing P/E (38. 4x forward), making it the more compelling value choice. Analysts rate Monster Beverage Corporation (MNST) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Monster Beverage Corporation (MNST) is the cheapest at 39.

2x versus Celsius Holdings, Inc. at 137. 0x. On forward P/E, Celsius Holdings, Inc. is actually cheaper at 19. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Celsius Holdings, Inc. wins at 0. 43x versus Monster Beverage Corporation's 4. 80x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -95. 0% for XWELL, Inc. (XWEL). Over 10 years, the gap is even starker: CELH returned +38. 9% versus XWEL's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Monster Beverage Corporation (MNST) is the lower-risk stock at 0.

34β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately 625% more volatile than MNST relative to the S&P 500. On balance sheet safety, Celsius Holdings, Inc. (CELH) carries a lower debt/equity ratio of 23% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Celsius Holdings, Inc.

(CELH) is pulling ahead at 85. 5% versus -13. 8% for XWELL, Inc. (XWEL). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -44. 4% for Celsius Holdings, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Monster Beverage Corporation (MNST) is the more profitable company, earning 23.

0% net margin versus -58. 2% for XWELL, Inc. — meaning it keeps 23. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MNST leads at 29. 2% versus -32. 0% for XWEL. At the gross margin level — before operating expenses — SKIN leads at 65. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Celsius Holdings, Inc. (CELH) is the more undervalued stock at a PEG of 0. 43x versus Monster Beverage Corporation's 4. 80x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Celsius Holdings, Inc. (CELH) trades at 19. 9x forward P/E versus 58. 3x for Hims & Hers Health, Inc. — 38. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CELH: 61. 7% to $55. 40.

In this comparison, XWEL (3.

8% yield), CELH (0. 5% yield) pay a dividend. MNST, HIMS, SKIN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Monster Beverage Corporation (MNST) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

34), +248. 0% 10Y return). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 48 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MNST: +248. 0%, HIMS: +188. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (XWEL (Consumer Cyclical) and MNST (Consumer Defensive) and HIMS (Healthcare) and CELH (Consumer Defensive) and SKIN (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: XWEL is a small-cap income-oriented stock; MNST is a mid-cap quality compounder stock; HIMS is a small-cap high-growth stock; CELH is a small-cap high-growth stock; SKIN is a small-cap quality compounder stock. XWEL pays a dividend while MNST, HIMS, CELH, SKIN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.